BOCOM International cut its PT for Yunding Xinyao (01952.HK) to HKD66 and maintained a Buy rating. The bank lowered 2026–2028 revenue forecasts by 15–18% and trimmed long‑term peak sales assumptions for Naifukang, citing intensifying competition and short‑term supply tightness for Yijia. Naifukang continued strong sales growth in 1H26; the company is localizing production of Yijia and Weishiping to mitigate overseas supply‑chain risk. Management reiterated a dual inbound/outbound BD strategy, le

BOCOM International cut its PT for Yunding Xinyao (01952.HK) to HKD66 and maintained a Buy rating. The bank lowered 2026–2028 revenue forecasts by 15–18% and trimmed long‑term peak sales assumptions for Naifukang, citing intensifying competition and short‑term supply tightness for Yijia. Naifukang continued strong sales growth in 1H26; the company is localizing production of Yijia and Weishiping to mitigate overseas supply‑chain risk. Management reiterated a dual inbound/outbound BD strategy, leveraging mRNA capability, a validated commercial platform and Hisun’s Southeast Asia footprint to pursue early‑stage in‑licensing/partnering and late‑stage/commercial collaborations.